Novo Nordisk A/S (NVO)
| Market Cap | 167.68B -47.6% |
| Revenue (ttm) | 48.59B +6.4% |
| Net Income | 16.10B +1.4% |
| EPS | 3.62 +1.8% |
| Shares Out | 4.44B |
| PE Ratio | 10.41 |
| Forward PE | 11.58 |
| Dividend | $1.29 (3.43%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 11,397,901 |
| Open | 38.30 |
| Previous Close | 37.44 |
| Day's Range | 37.42 - 38.42 |
| 52-Week Range | 35.12 - 81.44 |
| Beta | 0.27 |
| Analysts | Hold |
| Price Target | 51.00 (+35.93%) |
| Earnings Date | May 6, 2026 |
About NVO
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for NVO stock is "Hold." The 12-month stock price target is $51.0, which is an increase of 35.93% from the latest price.
News
Genetic variations linked to weight loss, side effects from GLP-1 drugs
Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe.
India's Weight Loss Drug Market: Eli Lilly (LLY) Faces Competition from Novo Nordisk (NVO)
India's Weight Loss Drug Market: Eli Lilly (LLY) Faces Competition from Novo Nordisk (NVO)
Novo Holdings Invests in Superconductors Amid EU Push for Fusion
Novo Holdings, the controlling shareholder of Novo Nordisk A/S, is topping up an investment in a Danish company specialized in superconductor technology, as part of an effort to accelerate new energy ...
Eli Lilly slips, Novo Nordisk holds firm as generic weight-loss drugs flood India
Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC's Annika Kim Constantino e...
Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC's Annika Kim Constantino e...
Novo Nordisk (NVO) Gains EMA Approval for Easier Wegovy Delivery
Novo Nordisk (NVO) Gains EMA Approval for Easier Wegovy Delivery
Eli Lilly Stock in Focus -- New Pill Launch Challenges Novo Nordisk
Eli Lilly Stock in Focus -- New Pill Launch Challenges Novo Nordisk
Novo Nordisk's (NVO) Semaglutide Gains Ground in India, Pressures Eli Lilly (LLY)
Novo Nordisk's (NVO) Semaglutide Gains Ground in India, Pressures Eli Lilly (LLY)
Asia’s flood of cheap Ozempic generics opens gates to weight-loss abuse
As Asia grappled with the impact of the Iran war, a major pharmaceutical milestone quietly made the headlines. On March 20, the patent for semaglutide, the active ingredient in Novo Nordisk’s Ozempic ...
Which of These Healthcare Stocks Is More Likely to Be a Millionaire Maker?
These two companies operate in a high-growth market, one that's heading toward $100 billion, according to analysts' forecasts. Their products have brought in blockbuster revenue.
3 Absurdly Cheap Dividend Stocks to Buy in April 2026
AbbVie, Novo Nordisk, and Verizon Communications are stellar dividend stocks with strong financials. These stocks pay between 3.4% and 5.8% in dividends.
A high dose of Wegovy will cost $50 less than Zepbound
Novo Nordisk launched the high dose version of its GLP-1 injection at a price that’s $50 lower than the one for Eli Lilly’s competing drug.
Why Novo Nordisk's Weight Loss Pill Has Taken Off
Novo Nordisk's weight loss pill is expanding the obesity treatment market as an alternative to injectable GLP-1 medications. CNBC spoke with patients about their experience on the pill and explains ho...
NVO: Novo Nordisk Launches Higher Dose Wegovy in the U.S.
NVO: Novo Nordisk Launches Higher Dose Wegovy in the U.S.
Can Wegovy HD 7.2 mg drive Novo Nordisk's obesity drug rebound?
Novo Nordisk announced on Tuesday that it is making a higher-dose version of its popular weight-loss medication, Wegovy, available across the United States. The new 7.2-milligram dose, branded as Weg...
Novo Nordisk Unveils $399 Wegovy HD, Undercutting Lilly By About 40%
Novo Nordisk Unveils $399 Wegovy HD, Undercutting Lilly By About 40%
Novo Nordisk Launches Higher-Dose Wegovy Weight-Loss Shot in U.S.
Wegovy HD—offering the highest weight-loss of any Wegovy injection so far—is now available nationwide, the compay said.
Novo Nordisk launches higher-dose Wegovy in the United States
Novo Nordisk said on Tuesday that it has made a higher-dose version of its blockbuster weight-loss drug Wegovy available across the United States.
Trump's Iran deadline, the Altman-Musk feud, Novo's Wegovy pill and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
Novo Nordisk's new Wegovy GLP-1 pill appears to be expanding the obesity treatment market, drawing in new patients rather than converting existing ones from injections. CNBC spoke with five U.S. patie...
How Novo Nordisk's weight loss pill is drawing in new patients for obesity treatment
Novo Nordisk's latest GLP-1 weight loss drug comes in pill form. Its ease of access has drawn in new obesity patients who may have opted against its injectable predecessor. After the drug's first few ...
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 7 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council ...
Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight
The U.S. Food & Drug Administration just approved Eli Lilly's GLP-1 pill orforglipron.
Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market
The market for weight loss drugs still has plenty of room to grow. Novo Nordisk's new subscription model for Wegovy could help expand its reach.